Chemed's $62.5M Roto-Rooter Buyback: 12-18 Month Integration Timeline Explained
Seeking Alpha · October 28, 2026
Key takeaways
- Chemed is buying back a California Roto-Rooter franchise for $62.5 million, with a 12-18 month integration timeline.
- VITAS hospice revenue grew 12.2% year over year to $457.4 million, while Medicare cap exposure dropped sharply in Florida.
- Chemed expects full-year 2026 EPS to hit or slightly exceed the high end of prior guidance despite rising Roto-Rooter marketing costs.
What Happened Chemed, the parent company behind both VITAS Healthcare and Roto-Rooter, laid out fresh details on its Q3 2026 earnings call — and there's a lot going on under one corporate roof. The headline news: Chemed is buying back a California Roto-Rooter franchise for $62.5 million, with management expecting a 12- to 18-month window to fully integrate it into company operations.
On the healthcare side, VITAS (the hospice division) posted a strong quarter, with revenue climbing 12.2% year over year to $457.4 million. CEO Kevin McNamara credited average daily census (ADC) growth and tighter cost controls, especially around central support spending. Admissions hit 18,995 for the quarter, and the company says it's keeping Florida's patient mix stable — a key regulatory and reimbursement consideration given how Medicare cap rules work state by state.
Why the Roto-Rooter Side Matters Roto-Rooter, the plumbing and drain services brand, saw same-store revenue grow 5.5%, but it wasn't all smooth. Management flagged rising customer acquisition costs — lead generation got pricier, pushing marketing spend up $4.3 million year over year as the company leaned more into paid leads. That's a notable headwind in a business that depends heavily on being the first call when someone's pipes back up.
The California franchise buyback signals Chemed wants more direct control over a key market rather than leaving it to a third-party operator. Buybacks like this usually aim to capture more margin and standardize service quality, but they come with real integration costs and operational risk — hence the 12- to 18-month runway management is giving itself.
The Financial Picture On the hospice side, Medicare cap exposure improved significantly. Chemed ended the 2026 Medicare cap year with a cushion of more than $34 million in its Florida combined program, and accrued just $828,000 in Medicare cap billing limitations — down sharply from $6.1 million a year earlier. That's a big swing, and it suggests better patient mix management and reimbursement strategy are paying off.
Putting it all together, Chemed says it expects 2026 earnings per share to land at or slightly above the prior high end of its guidance range. That's a meaningful signal of confidence, especially with new integration costs on the horizon from the California deal.
What to Watch Keep an eye on how quickly Roto-Rooter can offset rising marketing costs with scale from the California buyback, and whether VITAS can sustain its hospital admission mix as it continues to grow ADC. Both segments are doing the heavy lifting for Chemed's overall earnings story right now.
Why it matters
Chemed's dual business model — hospice care and home services — makes it a useful bellwether for both healthcare reimbursement trends and consumer services spending. Investors and industry watchers get a rare look at how a diversified holding company balances regulatory-sensitive healthcare growth with franchise-driven consumer business expansion.
Want deals on what you love?
Val finds local offers matched to your interests — free to start.
Meet Val